MEDICAL SERVICES

Specialties

Departments

Programs

Languages

  • English

EDUCATION

Graduate Degree

PhD, Cell Biology
  • University of Pittsburgh School of Medicine , 2007 , Pittsburgh , MA

Medical School

  • University of Pittsburgh School of Medicine , 2009 , Pittsburgh , PA

Internship

  • St. Vincent Hospital , 2010 , Worcester , MA

Residency

  • Harvard Medical School , 2013 , Boston , MA

Fellowship

  • Boston Children's Hospital , 2014 , Boston , MA

PROFESSIONAL HISTORY

Dr. Elena Hawryluk is a board-certified Pediatric Dermatologist and Assistant Professor of Dermatology at Harvard Medical School.  She has a special interest in pigmented lesions in children, including melanoma, spitz nevi, congenital nevi, acquired nevi, and pigmentary birthmarks.  Her academic and research interests have been supported by the Society for Pediatric Dermatology, the Pediatric Dermatology Research Alliance, and the Dermatology Foundation’s Career Development Award. 

CERTIFICATIONS

  • American Board of Dermatology, Pediatric Dermatology

PUBLICATIONS

Publications powered by Harvard Catalyst Profiles

  1. Bartenstein DW, Fisher JM, Stamoulis C, Weldon C, Huang JT, Gellis SE, Liang MG, Schmidt B, Hawryluk EB. Clinical features and outcomes of spitzoid proliferations in children and adolescents. Br J Dermatol. 2018 Nov 22. View abstract
  2. Klebanov N, Gunasekera NS, Lin WM, Hawryluk EB, Miller DM, Reddy BY, Christman MP, Beaulieu D, Rajadurai S, Duncan LM, Sober AJ, Tsao H. Clinical spectrum of cutaneous melanoma morphology. J Am Acad Dermatol. 2018 Aug 28. View abstract
  3. Rea CJ, Tran KD, Jorina M, Wenren LM, Hawryluk EB, Toomey SL. Associations of Eczema Severity and Parent Knowledge With Child Quality of Life in a Pediatric Primary Care Population. Clin Pediatr (Phila). 2018 Nov; 57(13):1506-1514. View abstract
  4. Huang JT, Song JS, Hawryluk EB, London WB, Guo D, Sridharan M, Fisher DE, Lehmann LE, Duncan CN. Nonmalignant late cutaneous changes after allogeneic hematopoietic stem cell transplant in children. J Am Acad Dermatol. 2018 Aug; 79(2):230-237. View abstract
  5. Bartenstein DW, Kelleher CM, Friedmann AM, Duncan LM, Tsao H, Sober AJ, Hawryluk EB. Contrasting features of childhood and adolescent melanomas. Pediatr Dermatol. 2018 May; 35(3):354-360. View abstract
  6. Rea CJ, Tran KD, Jorina M, Wenren LM, Hawryluk EB, Toomey SL. A Randomized Controlled Trial of an Eczema Care Plan. Acad Pediatr. 2018 Sep - Oct; 18(7):789-796. View abstract
  7. Mccormack L, Hawryluk EB. Pediatric melanoma update. G Ital Dermatol Venereol. 2018 Oct; 153(5):707-715. View abstract
  8. Bartenstein DW, Coe TM, Gordon SC, Friedmann AM, Senna MM, Kelleher CM, Antonescu CR, Nazarian RM, Hawryluk EB. Lipofibromatosis-like neural tumor: Case report of a unique infantile presentation. JAAD Case Rep. 2018 Mar; 4(2):185-188. View abstract
  9. Gordon SC, Bartenstein DW, Tajmir SH, Song JS, Hawryluk EB. Delayed-type hypersensitivity to vaccine aluminum adjuvant causing subcutaneous leg mass and urticaria in a child. Pediatr Dermatol. 2018 Mar; 35(2):234-236. View abstract
  10. Song JS, London WB, Hawryluk EB, Guo D, Sridharan M, Fisher DE, Lehmann LE, Duncan CN, Huang JT. Risk of melanocytic nevi and nonmelanoma skin cancer in children after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2017 Jul; 52(7):989-997. View abstract
  11. Bartenstein DW, Song JS, Nazarian RM, Hawryluk EB. Evolving Childhood Melanoma Monitored by Parental Photodocumentation. J Pediatr. 2017 Jul; 186:205-205.e1. View abstract
  12. Song H, Song JS, Merola MC, Nazarian RM, Hawryluk EB. Pigmented purpuric dermatosis: a striking but benign cutaneous entity. Arch Dis Child. 2017 Dec; 102(12):1157. View abstract
  13. LeBovidge JS, Elverson W, Timmons KG, Hawryluk EB, Rea C, Lee M, Schneider LC. Multidisciplinary interventions in the management of atopic dermatitis. J Allergy Clin Immunol. 2016 08; 138(2):325-34. View abstract
  14. Hawryluk EB, Schmidt B, Maguiness S. Enlargement of eccrine angiomatous hamartoma following trauma. Pediatr Dermatol. 2015 May-Jun; 32(3):e92-4. View abstract
  15. Sheu J, Hawryluk EB, Guo D, London WB, Huang JT. Voriconazole phototoxicity in children: a retrospective review. J Am Acad Dermatol. 2015 Feb; 72(2):314-20. View abstract
  16. Sheu J, Hawryluk EB, Litsas G, Thakuria M, LeBoeuf NR. Papulopustular acneiform eruptions resulting from trastuzumab, a HER2 inhibitor. Clin Breast Cancer. 2015 Feb; 15(1):e77-81. View abstract
  17. Hawryluk EB, Tsao H. Melanoma: clinical features and genomic insights. Cold Spring Harb Perspect Med. 2014 Sep 02; 4(9):a015388. View abstract
  18. Park JJ, Hawryluk EB, Tahan SR, Flaherty K, Kim CC. Cutaneous granulomatous eruption and successful response to potent topical steroids in patients undergoing targeted BRAF inhibitor treatment for metastatic melanoma. JAMA Dermatol. 2014 Mar; 150(3):307-11. View abstract
  19. Hawryluk EB, Liang MG. Pediatric melanoma, moles, and sun safety. Pediatr Clin North Am. 2014 Apr; 61(2):279-91. View abstract
  20. Alloo A, Strazzula L, Rothschild B, Hawryluk E, Levine D, Hoang MP, Koga H, Hashimoto T, Kroshinsky D. Refractory antilaminin ?1 pemphigoid successfully treated with intravenous immunoglobulin and mycophenolate mofetil. J Eur Acad Dermatol Venereol. 2014 Oct; 28(10):1401-3. View abstract
  21. Haq R, Yokoyama S, Hawryluk EB, Jönsson GB, Frederick DT, McHenry K, Porter D, Tran TN, Love KT, Langer R, Anderson DG, Garraway LA, Duncan LM, Morton DL, Hoon DS, Wargo JA, Song JS, Fisher DE. BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proc Natl Acad Sci U S A. 2013 Mar 12; 110(11):4321-6. View abstract
  22. Hawryluk EB, Baran JL, Gerami P, Sepehr A. 'Monster cell' melanoma with pulmonary metastasis and cyclin D1 amplification. J Cutan Pathol. 2013 Jan; 40(1):61-5. View abstract
  23. Hawryluk EB, O'Regan KN, Sheehy N, Guo Y, Dorosario A, Sakellis CG, Jacene HA, Wang LC. Positron emission tomography/computed tomography imaging in Merkel cell carcinoma: a study of 270 scans in 97 patients at the Dana-Farber/Brigham and Women's Cancer Center. J Am Acad Dermatol. 2013 Apr; 68(4):592-599. View abstract
  24. Hanash AM, Dudakov JA, Hua G, O'Connor MH, Young LF, Singer NV, West ML, Jenq RR, Holland AM, Kappel LW, Ghosh A, Tsai JJ, Rao UK, Yim NL, Smith OM, Velardi E, Hawryluk EB, Murphy GF, Liu C, Fouser LA, Kolesnick R, Blazar BR, van den Brink MR. Interleukin-22 protects intestinal stem cells from immune-mediated tissue damage and regulates sensitivity to graft versus host disease. Immunity. 2012 Aug 24; 37(2):339-50. View abstract
  25. Sheikine Y, Hawryluk EB, Burgin S, Zimarowski MJ. Histopathology of measles exanthem: a case with characteristic features and eosinophils. J Cutan Pathol. 2012 Jul; 39(7):667-70. View abstract
  26. Hawryluk EB, Linskey KR, Duncan LM, Nazarian RM. Broad range of adverse cutaneous eruptions in patients on TNF-alpha antagonists. J Cutan Pathol. 2012 May; 39(5):481-92. View abstract
  27. Hawryluk EB, Sober AJ, Piris A, Nazarian RM, Hoang MP, Tsao H, Mihm MC, Duncan LM. Histologically challenging melanocytic tumors referred to a tertiary care pigmented lesion clinic. J Am Acad Dermatol. 2012 Oct; 67(4):727-35. View abstract
  28. Ko J, Hawryluk E, Taylor CR. Part II: high-yield dermatologic signs the Harvard combined program in dermatology. J Drugs Dermatol. 2011 Feb; 10(2):197-8. View abstract
  29. Hawryluk EB, Penn SK, Wasko MC, Johnson JT, Ferris LK. Treatment of postsurgical pyoderma gangrenosum with a high-potency topical steroid. Ear Nose Throat J. 2010 Jun; 89(6):E5-7. View abstract
  30. Hawryluk EB, Izikson L, English JC. Non-infectious granulomatous diseases of the skin and their associated systemic diseases: an evidence-based update to important clinical questions. Am J Clin Dermatol. 2010; 11(3):171-81. View abstract
  31. Hawryluk EB, English JC. Female adolescent hair disorders. J Pediatr Adolesc Gynecol. 2009 Aug; 22(4):271-81. View abstract
  32. Spencer LA, Hawryluk EB, English JC. Lichen planopilaris: retrospective study and stepwise therapeutic approach. Arch Dermatol. 2009 Mar; 145(3):333-4. View abstract
  33. Khandelwal P, Ruiz WG, Balestreire-Hawryluk E, Weisz OA, Goldenring JR, Apodaca G. Rab11a-dependent exocytosis of discoidal/fusiform vesicles in bladder umbrella cells. Proc Natl Acad Sci U S A. 2008 Oct 14; 105(41):15773-8. View abstract
  34. Studeny S, Cheppudira BP, Meyers S, Balestreire EM, Apodaca G, Birder LA, Braas KM, Waschek JA, May V, Vizzard MA. Urinary bladder function and somatic sensitivity in vasoactive intestinal polypeptide (VIP)-/- mice. J Mol Neurosci. 2008 Nov; 36(1-3):175-87. View abstract
  35. Balestreire E, Haught JM, English JC. Multiple subcutaneous lipomas induced by HAART in the absence of protease inhibitors. Arch Dermatol. 2007 Dec; 143(12):1596-7. View abstract
  36. Apodaca G, Balestreire E, Birder LA. The uroepithelial-associated sensory web. Kidney Int. 2007 Nov; 72(9):1057-64. View abstract
  37. Balestreire EM, Apodaca G. Apical epidermal growth factor receptor signaling: regulation of stretch-dependent exocytosis in bladder umbrella cells. Mol Biol Cell. 2007 Apr; 18(4):1312-23. View abstract
  38. Wang EC, Lee JM, Ruiz WG, Balestreire EM, von Bodungen M, Barrick S, Cockayne DA, Birder LA, Apodaca G. ATP and purinergic receptor-dependent membrane traffic in bladder umbrella cells. J Clin Invest. 2005 Sep; 115(9):2412-22. View abstract
  39. Rhodes ME, Balestreire EM, Czambel RK, Rubin RT. Estrous cycle influences on sexual diergism of HPA axis responses to cholinergic stimulation in rats. Brain Res Bull. 2002 Nov 30; 59(3):217-25. View abstract